August M&A Analysis: Slow Month Highlighted By Unique Technologies
The dog-days of summer produced just a handful of mergers and acquisitions in the medtech sector and no blockbuster deals. However, several companies made smaller deals for innovative products in a range of sectors including IVDs, cardiovascular devices, and ophthalmology.
You may also be interested in...
Myriad's GeneSight Psychotropic Genetic Test Improves Depression Therapy In Trial
Results of a randomized trial presented at the American Psychiatric Association conference show the GeneSight Psychotropic genetic test can improve the treatment of depression by identifying the medications most and least likely to be effective.
Zimmer Biomet Adds CD Diagnostics To List Of 2016 Acquisitions
The deal will add musculoskeletal diagnostic tests to Zimmer Biomet's new Signature Solutions consulting and technology program. It is the orthopedics giant's sixth acquisition of 2016.
M&A Analysis: Slow Month Highlighted By A Few Big Deals
Medical device mergers and acquisitions in July include LabCorps’ $371m deal for Sequenom and Zimmer Biomet’s acquisition of spine surgery robot-maker Medtech SA.